Last reviewed · How we verify
CD19-BCMA Targeted CAR-T Dose 1
At a glance
| Generic name | CD19-BCMA Targeted CAR-T Dose 1 |
|---|---|
| Sponsor | Ting Chang, MD |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT (PHASE1, PHASE2)
- A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE (PHASE1, PHASE2)
- A Clinical Study of Dual-Target, Universal CAR-T Cell Therapy for Refractory Systemic Lupus Erythematosus (PHASE1)
- Autologous CAR-T Cell Therapy for Refractory and Relapsing Ulcerative Colitis: A Single-Center Exploratory Study (EARLY_PHASE1)
- A Clinical Study Evaluating the Safety and Preliminary Efficacy of Universal Allogeneic CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C)in Patients With Refractory Primary Immune Thrombocytopenia (EARLY_PHASE1)
- CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases (EARLY_PHASE1)
- Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases (PHASE1)
- Safety and Efficacy of CD19-BCMA Targeted CAR-T Therapy for Refractory Generalized Myasthenia Gravis (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CD19-BCMA Targeted CAR-T Dose 1 CI brief — competitive landscape report
- CD19-BCMA Targeted CAR-T Dose 1 updates RSS · CI watch RSS
- Ting Chang, MD portfolio CI